Use of gastrografin in the management of faecal impaction in patients with severe chronic constipation: a randomized clinical trial.

Abstract

BACKGROUND/AIM:

Faecal impaction (FI) is a common cause of lower gastrointestinal tract obstruction. Gastrografin is a water-soluble radiologic contrast agent that may be orally or rectally administered, with proved therapeutic benefits in adhesive small bowel obstruction. Enemas have long been advocated as the best treatment for FI. The purpose of this study was to demonstrate that enteral administration of gastrografin might be more effective than enema in FI treatment inducing intestinal obstruction.

METHODS:

A double-blinded, controlled and randomized trial was conducted. Participants received 100 mL of gastrografin (gastrografin group) through nasointestinal tube or enemas (enema group) once daily for six consecutive days. Successful faecal disimpaction, FI time to resolution, Bristol Stool Scale, constipation severity, symptom assessment and adverse events were evaluated.

RESULTS:

A total of 124 patients were eligible, but only 83 were enrolled to this trial (mean age: 44 ± 15.8 years). Forty-two patients received enemas, and 41 patients received gastrografin, with six dropouts in each group. Successful disimpaction was achieved with enemas (69.44%) and gastrografin (88.57%; P = 0.034), mean duration of impaction was strikingly different between the two groups (67.13 versus 31.67, respectively; P < 0.01). Constipation severity and symptom assessment were significantly reduced in the gastrografin group.

CONCLUSION:

Gastrografin given through nasointestinal tube was more effective than enema in the treatment of FI inducing colon obstruction. Gastrografin might be taken into consideration as an effective and safe therapeutic option for FI.

• Authors: Lili Gu, Chao Ding, Hongliang Tian, Bo Yang, Xuelei Zhang, Yue Hua, Jianfeng Gong, Ning Li
• Journal: ANZ journal of surgery (ANZ J Surg) Vol. 89 Issue 3 Pg. 239-243 (03 2019) ISSN: 1445-2197 [Electronic] Australia
• PMID: 30294848 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: © 2018 Royal Australasian College of Surgeons.

Chemical References

• Diatrizoate Meglumine

Topics

• Adolescent
• Adult
• Aged
• Constipation (complications)
• Diatrizoate Meglumine (therapeutic use)
• Double-Blind Method
• Enema
• Fecal Impaction (drug therapy, etiology, therapy)
• Female
• Humans
• Male
• Middle Aged
• Prospective Studies
• Severity of Illness Index
• Young Adult